INLF:NASDAQINLIF LIMITED Analysis
Data as of 2026-05-19 - not real-time
$4.13
Latest Price
8/10Risk
Risk Level: High
Executive Summary
INLIF Limited operates in the specialty industrial machinery sector in China and is listed on NASDAQ. The stock trades well below its long‑term moving average and far above a discounted‑cash‑flow fair value, creating a stark valuation gap. While the price‑to‑book multiple is low, earnings are strongly negative, operating cash flow is deficient, and the balance sheet shows a high debt‑to‑equity ratio, suggesting fundamental weakness.
Technical indicators present a mixed signal: the 20‑day SMA lies under the current price, the 50‑day SMA sits above, MACD has turned bullish, and RSI is near the midpoint, indicating no clear overbought or oversold condition. Volume is increasing but overall trading activity remains thin, and 30‑day volatility exceeds 100%, amplifying risk. The company faces high sector and geographic risk, moderate regulatory exposure, and negligible market beta, making the equity highly speculative.
Technical indicators present a mixed signal: the 20‑day SMA lies under the current price, the 50‑day SMA sits above, MACD has turned bullish, and RSI is near the midpoint, indicating no clear overbought or oversold condition. Volume is increasing but overall trading activity remains thin, and 30‑day volatility exceeds 100%, amplifying risk. The company faces high sector and geographic risk, moderate regulatory exposure, and negligible market beta, making the equity highly speculative.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- price below long‑term SMA suggests downward pressure
- extreme short‑term volatility
- thin trading volume increasing liquidity risk
Medium Term
1–3 yearsCautious
Model confidence: 5/10
Key Factors
- persistent negative earnings and cash flow
- DCF fair value far below market price
- high debt load relative to equity
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- structural weakness in profitability and margins
- exposure to Chinese manufacturing cycle and regulatory environment
- lack of dividend and analyst coverage limiting upside catalysts
Key Metrics & Analysis
Financial Health
Revenue Growth-10.20%
Profit Margin-29.59%
ROE-41.26%
ROA-16.82%
Debt/Equity30.82
P/B Ratio0.3
Op. Cash Flow$-1890612
Free Cash Flow$1.1M
Industry P/E29.5
Technical Analysis
TrendBearish
RSI50.5
Support$3.01
Resistance$4.69
MA 20$3.79
MA 50$4.37
MA 200$9.54
MACDBullish
VolumeIncreasing
Fear & Greed Index89.61
Valuation
Fair Value$1.16
GradeOvervalued
TypeValue
Risk Assessment
Beta0.02
Volatility106.42%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.